A 28-year-old woman from Delhi presents with irregular menstrual cycles for the past 3 years. She reports oligomenorrhea (cycles ranging from 45 to 90 days), excessive facial hair, and acne. On examination, she has a BMI of 32 kg/m², hirsutism (Ferriman–Gallwey score 18), and acanthosis nigricans on the neck. Pelvic ultrasound shows bilateral ovarian cysts (10 mm) with increased stromal echogenicity. Fasting blood glucose is 105 mg/dL. LH:FSH ratio is 3.2:1. What is the most appropriate first-line pharmacological intervention for her menstrual irregularity and hyperandrogenism?

Question

A 28-year-old woman from Delhi presents with irregular menstrual cycles for the past 3 years. She reports oligomenorrhea (cycles ranging from 45 to 90 days), excessive facial hair, and acne. On examination, she has a BMI of 32 kg/m², hirsutism (Ferriman–Gallwey score 18), and acanthosis nigricans on the neck. Pelvic ultrasound shows bilateral ovarian cysts (>10 mm) with increased stromal echogenicity. Fasting blood glucose is 105 mg/dL. LH:FSH ratio is 3.2:1. What is the most appropriate first-line pharmacological intervention for her menstrual irregularity and hyperandrogenism?

Accepted Answer

D. Combined oral contraceptive pill containing ethinyl estradiol and cyproterone acetate. ## Clinical Diagnosis

This patient meets Rotterdam criteria for PCOD (polycystic ovary disease):
- Oligomenorrhea (irregular cycles)
- Clinical hyperandrogenism (hirsutism, acne)
- Polycystic ovarian morphology on ultrasound
- Elevated LH:FSH ratio (typically >2.5–3:1 in PCOD)

**Key Point:** The Rotterdam criteria require ≥2 of 3 features: (1) anovulation/oligomenorrhea, (2) clinical or biochemical hyperandrogenism, (3) polycystic ovaries on imaging. This patient has all three.

## First-Line Management Approach

### For Menstrual Irregularity + Hyperandrogenism

| Intervention | Mechanism | Indication | Limitation |
|---|---|---|---|
| **Combined OCP** | Suppresses LH → ↓ ovarian androgen; ↑ SHBG → ↓ free androgens | First-line for menstrual regulation + anti-androgenic effects | Contraindicated in thrombophilia; not suitable if fertility desired |
| **Metformin** | Improves insulin sensitivity; ↓ hyperinsulinemia | First-line if metabolic dysfunction/impaired fasting glucose/diabetes risk | Slower onset; primarily for metabolic features |
| **Spironolactone** | Aldosterone antagonist; anti-androgenic | Adjunct for hirsutism/acne; NOT for menstrual regulation | Does not restore ovulatory cycles |
| **GnRH agonist** | Suppresses pituitary gonadotropins | Severe hyperandrogenism refractory to other agents; NOT first-line | Expensive; induces hypogonadism; requires add-back therapy |

**High-Yield:** Combined OCP is the **gold standard first-line** for PCOD patients with menstrual irregularity and clinical hyperandrogenism who do not desire immediate pregnancy. It addresses both problems simultaneously.

### Why This Patient Needs OCP

1. **Menstrual regulation:** Exogenous estrogen + progestin suppress GnRH pulsatility → ↓ LH → ↓ ovarian androgen production.
2. **Anti-androgenic effect:** Estrogen ↑ SHBG (sex hormone–binding globulin) → ↓ free testosterone; progestin (especially cyproterone acetate) blocks androgen receptors.
3. **Metabolic consideration:** Although she has impaired fasting glucose (105 mg/dL), metformin is typically added as second-line if metabolic dysfunction persists or if she desires pregnancy (off OCP).

**Clinical Pearl:** Cyproterone acetate–containing OCPs (e.g., Diane-35, Yasmin) are preferred in PCOD with prominent hyperandrogenic symptoms (hirsutism, acne) because the progestin component has anti-androgenic activity.

## Why Metformin Is Not First-Line Here

**Key Point:** Metformin is first-line **only** if the patient has:
- Impaired glucose tolerance or type 2 diabetes, OR
- Desire for pregnancy (off hormonal contraception)

This patient has fasting glucose 105 mg/dL (impaired fasting glucose, IFG), which is borderline. However, for **menstrual regulation and hyperandrogenism control**, OCP is superior and faster-acting. Metformin can be added later if metabolic features worsen or if she plans pregnancy.

**Mnemonic: PCOD First-Line Therapy — "METRO"**
- **M**enstrual irregularity → **OCP** (first-line)
- **E**xcessive androgens → **OCP** (first-line)
- **T**ype 2 diabetes risk → **Metformin** (add if IFG/diabetes)
- **R**efractory hirsutism → **Spironolactone** (adjunct)
- **O**besity/weight loss → **Lifestyle** (always concurrent)

## Treatment Algorithm

```mermaid
flowchart TD
  A[PCOD diagnosis confirmed]:::outcome --> B{Clinical presentation?}:::decision
  B -->|Menstrual irregularity + hyperandrogenism| C[Combined OCP]:::action
  B -->|Metabolic dysfunction/IFG/T2DM| D[Metformin ± OCP]:::action
  B -->|Desire pregnancy| E[Metformin + lifestyle]:::action
  C --> F{Hirsutism refractory?}:::decision
  F -->|Yes| G[Add spironolactone]:::action
  F -->|No| H[Continue OCP + lifestyle]:::action
  D --> I[Monitor glucose, lipids]:::action
  E --> J[Induce ovulation if needed]:::action
```

**High-Yield:** Always combine pharmacotherapy with lifestyle modification (weight loss 5–10%, exercise, dietary changes) — this improves insulin sensitivity and reduces androgen levels.

Answer

A. Metformin 1500 mg daily

Answer

B. Leuprolide acetate 3.75 mg intramuscularly monthly

Answer

C. Spironolactone 100 mg daily

Explanation

Practice similar questions